The long-acting multiple sclerosis treatment that the U.S. Food and Drug Administration approved late last week will be manufactured in Research Triangle Park. The drug, Zinbryta, will be manufactured by Biogen (Nasdaq: BIIB), which is based in Cambridge, Massachusetts, and has a major production outfit in RTP. Bingen received FDA approval for the once-a-month treatment together with AbbVie (NYSE: ABBV). Although Zinbryta showed higher efficacy in treating MS, Biogen recommends that patients take… (Source: bizjournals.com Health Care:Biotechnology headlines)